Open Nav

ArTara Therapeutics, Inc.

  • Jesse Shefferman, ArTara Therapeutics, Inc.

Raise investor awareness of our company ahead of our upcoming second capital raise

  • Date:Wednesday, October 17
  • Time:10:15 AM - 10:30 AM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:ArTara is a rare diseases company focused on developing de-risked assets that will have real-world impact on the lives of patients suffering from rare diseases. Our lead program, IV Choline Chloride, is an easy to understand replacement therapy for Intestinal Failure Associated Liver Disease, a fatal rare disease that affects the thousands of chronically ill patients who survive on intravenous nutrition. There are no approved therapies for IFALD. IV Choline has demonstrated promising results in IFALD patients in two Phase II studies and is further supported by decades of academic research. We are currently in End-of-Phase-2 dialogue with the FDA to outline and agree on the pivotal program design for IV Choline and anticipate we will reach agreement by end-2018. Beyond IV Choline we are active in bringing new rare disease programs to the ArTara portfolio and anticipate growth in our portfolio through 2018-2019.
  • Company
  • Company HQ City:New York City
  • Company HQ Country:United States
  • Company HQ State:New York                    
  • CEO/Top Company Official:Jesse Shefferman, CEO
  • Year Founded:2017
  • Main Therapeutic Focus:Orphan/Rare Diseases
  • Lead Product in Development :IV Choline Chloride Replacement
  • Development Phase of Primary Product:Phase III
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :1
  • Additional Information/Comments:We were a finalist in the Buzz of BIO 2018 contest.
  • Previous and Current Investors:Private Family Office
  • Size of Last Investment Round:$5,021,500
  • Total Amount Raised to Date, In All Rounds:$5,021,500
Jesse Shefferman
ArTara Therapeutics, Inc.